Table 1.
Active EAE models with IFA or no adjuvant.
| Model | Antigen | Adjuvant | Clinical Course | Reference | |
|---|---|---|---|---|---|
| Monkeys |
Marmosets | rhMOG20-50
rhMOG14-36 rhMOG34-56 rhMOG74-96 |
IFA | Chronic/progressive | (53–55) |
| Marmosets Rhesus Cynomolgus |
rhMOG1-125 | IFA | Monophasic/relapsing/ progressive |
(56, 57) | |
| Rats | DA | rSCH | IFA | Protracted/relapsing | (58) |
| DA Lewis |
rSCH | IFA | Relapsing | (59) | |
| Lewis | rrMOG1-125 | IFA | Chronic/progressive | (60) | |
| DA | rmMOG1-116 | IFA | Chronic/relapsing | (61, 62) | |
| DA SD |
rhMOG1-125 | IFA | Benign to progressive | (63, 64) | |
| Lewis CD F |
gpSCH | No IFA |
NA | (65) | |
| DA | rSCH gpSCH |
No | Chronic/relapsing | (66–68) |
CD F, Fischer; DA, Dark Agouti; EAE, experimental autoimmune encephalomyelitis; gp, guinea pig; IFA, incoplete Freund’s adjuvant; MOG, myelin oligodendrocyte glycoprotein; NA – not addressed; r, rat; rh, recombinant human; rm, recombinant mouse; rr, recombinant rat; SCH, spinal cord homogenate; SD, Sprague Dawley.